age
Item
1. male or female patients 18 years or older
boolean
C0001779 (UMLS CUI [1])
eligible diagnoses
Item
2. eligible diagnoses: acute myelogenous leukemia (except apl) with > 10% bone marrow or peripheral blood blasts; failed to achieve cr or relapse after prior therapy, not candidates for potentially curative treatment. untreated patients > 60 are eligible if not candidates for standard induction. high-grade mds, defined by all the following features: ipss intermediate-2 or high risk; > 10% blasts on bone marrow examination; treatment failure from, or not candidates for, standard therapies including demethylating agents, eg azacytidine or decitabine.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
ECOG performance status
Item
3. eastern cooperative oncology group perf. status 0-2
boolean
C1520224 (UMLS CUI [1])
female patients
Item
4. female patients: postmenopausal for at least one year surgically sterile, or if childbearing potential, agree to practice two effective methods of contraception or abstain from heterosexual intercourse.
boolean
C0700589 (UMLS CUI [1])
C0232970 (UMLS CUI [2])
C0232920 (UMLS CUI [3])
male patients
Item
5. male patients: practice effective barrier contraception to one month after the last dose of study drug, or abstain from heterosexual intercourse.
boolean
C0700589 (UMLS CUI [1])
written consent
Item
6. voluntary written consent
boolean
C0021430 (UMLS CUI [1])
hydroxyurea
Item
7. patients on hydroxyurea may be included
boolean
C0020402 (UMLS CUI [1])
pregnancy or lactation
Item
1. pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV or aids-related illness
Item
2. known human immunodeficiency virus (hiv) positive or aids-related illness
boolean
C0019682 (UMLS CUI [1])
comorbidity that could interfere with the protocol completion
Item
3. serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the protocol completion
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
bilirubin
Item
4. total bilirubin > 1.5 × the upper limit of normal (uln)
boolean
C1278039 (UMLS CUI [1])
ALT, AST
Item
5. alanine aminotransferase (alt) and aspartate aminotransferase (ast) > 2.5 × the uln. ast, alt may be elevated to 5 x the uln if reasonably ascribed to underlying hematological disorder.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
creatinine clearance
Item
6. calculated creatinine clearance < 30 ml/minute
boolean
C0373595 (UMLS CUI [1])
chemotherapy or radiotherapy
Item
7. antineoplastic or radiotherapy within 14 days preceding the first dose
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
cardiac diseases
Item
8. myocardial infarction within 6 months of enrollment or current history of new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
boolean
C0018799 (UMLS CUI [1])
major surgery
Item
9. major surgery 14 days prior to the first dose
boolean
C0543467 (UMLS CUI [1])
cns leukemia
Item
10. clinically uncontrolled central nervous system (cns) involvement.
boolean
C1332884 (UMLS CUI [1])
inability to swallow capsule
Item
11. inability to swallow capsules
boolean
C0006935 (UMLS CUI [1])
sleep apnea or conditions that result in excessive daytime sleepiness
Item
12. history of uncontrolled sleep apnea or conditions that result in excessive daytime sleepiness, such as chronic lung disease
boolean
C0037315 (UMLS CUI [1])